The presence of FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation, common in acute myeloid leukemia (AML) but rare in MPAL, introduces further uncertainty regarding optimal treatment strategies, particularly regarding the use and timing of FLT3 inhibitors. Here, FLT3 is linked to mixed phenotype acute leukemia.